ROLE OF ASYMMETRIC DIMETHYLARGININE IN THE DEVELOPMENT OF CARDIOVASCULAR DISEASES
Ключевые слова:
myocardial infarction, endothelial dysfunction, asymmetric dimethylarginine, risk factors.Аннотация
The results of numerous studies in recent decades confirm the critical role of the vascular endothelium in the regulation of vascular homeostasis. A criterion for assessing the functional state of the endothelium is endothelium-dependent vasodilation, regulated by nitric oxide (NO). Despite clinical and experimental evidence of the relationship between increased plasma ADMA levels and the development of cardiovascular events, the clear etiopathogenetic role of ADMA in CVD requires further research. In order to accurately answer the question of whether ADMA is an etiological factor or a biological marker of CVD, additional analysis aimed at studying the biochemical, genetic and pharmacological aspects of ADMA metabolism is required, the results of which are presented in this article.
Библиографические ссылки
Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575.
Boger R.H., Cooke J.P., and Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc Med 2005;10 Suppl 1:S1–S2.
Creager M.A., Gallagher S.J., Girerd X.J., Coleman S.M., Dzau V.J., and Cooke J.P. L–Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248.
Jacobi J., and Tsao P.S. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008;28:224–237.
Masuda H., Goto M., Tamaoki S., and Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999;126:211–218.
Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O’Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198–203.
Böger R.H., Bode-Böger S.M., Szuba A., Tsao P.S., Chan J. R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction — its role in hypercholesterolemia. Circulation 1998;98:1842–1847.
Yada T., Kaji S., Akasaka T., Mochizuki S., Ogasawara Y., Tanemoto K., et al. Changes of asymmetric dimethylarginine, nitric oxide, tetrahydrobiopterin, and oxidative stress in patients with acute myocardial infarction by medical treatments. Clin Hemorheol Microcirc 2007;37:269–276.
Dayal S., Rodionov R.N., Arning E., Bottiglieri T., Kimoto M., Murry D.J., et al. Tissue-specific Downregulation of Dimethylarginine Dimethylaminohydrolase in Hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 2008;295(2): H816–25.
Leiper J.M., and Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006;62 Suppl 13:33–38.
Boger R.H., Sydow K., Borlak J., Thum T., Lenzen H., Schubert B., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99–105.
Li D., Xia K., Li N.S., Luo D., Wang S., Jiang D.J., et al. Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Can J Physiol Pharmacol 2007;85:783–789.
Di N.P., Taccardi A.A., Grilli A., De Lutiis M.A., Barsotti A., Felaco M., and De C.R. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res 2005;66:462–471.
Chen J.W., Hsu N.W., Wu T.C., Lin S.J., and Chang M. S. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002;90:974–982.
Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002;51:843–846.
